CI-980 in advanced melanoma and hormone refractory prostate cancer

Christopher W. Ryan, Keith L. Shulman, Jon M. Richards, John W. Kugler, Jeffrey A. Sosman, Rafat H. Ansari, Everett E. Vokes*, Nicholas J. Vogelzang

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Introduction: CI-980 is a novel chemotherapeutic agent that inhibits polymerization of tubulin. Preclinical studies have indicated a high level activity of this agent against various tumor cell lines. Methods: 13 malignant melanoma patients who had failed prior chemotherapy and/or immunotherapy and 13 hormone refractory prostate cancer patients, including 4 who had received prior chemotherapy, were treated in 2 separate NCI-supported clinical trials. Subjects received a recommended phase II dose of CI-980 of 4.5 mg/m2/day by continuous infusion for 72 hours every 3 weeks. Results: No activity was seen in either study. Toxicity was tolerable with neutropenia being the most common, significant toxicity. Among the melanoma patients, 15% and 31% developed grade 3 and grade 4 neutropenia, while 7% and 38% of the prostate patients developed grade 3 and grade 4 neutropenia, respectively. Conclusions: CI-980 at this dose and schedule is ineffective against malignant melanoma and hormone refractory prostate cancer.

Original languageEnglish (US)
Pages (from-to)187-191
Number of pages5
JournalInvestigational New Drugs
Issue number2
StatePublished - 2000


  • Chemotherapy
  • Clinical trial
  • Malignant melanoma
  • Prostate cancer

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology
  • Pharmacology


Dive into the research topics of 'CI-980 in advanced melanoma and hormone refractory prostate cancer'. Together they form a unique fingerprint.

Cite this